TABLE 5.

Power for different tests for HZ Pain and infection in a Phase III zoster vaccine trial

VE (%)	p C	p V	Δ	μ C	μ V	V E BOI	BOI	CH‐LW	FCM	prop	inf
0	0.15	0.1500	0.0	4.50	4.50	0.024	0.023	0.024	0.024	0.024	0.026
15	0.15	0.1275	0.0	4.50	4.50	0.239	0.235	0.202	0.186	0.267	0.025
30	0.15	0.1050	0.0	4.50	4.50	0.757	0.752	0.680	0.683	0.801	0.023
0	0.15	0.1500	0.4	4.50	4.10	0.114	0.109	0.206	0.426	0.023	0.556
15	0.15	0.1275	0.4	4.50	4.10	0.502	0.495	0.590	0.650	0.268	0.529
30	0.15	0.1050	0.4	4.50	4.10	0.910	0.906	0.921	0.910	0.802	0.497
0	0.15	0.1500	0.8	4.50	3.70	0.351	0.344	0.598	0.967	0.026	0.988
15	0.15	0.1275	0.8	4.50	3.70	0.782	0.775	0.906	0.982	0.268	0.981
30	0.15	0.1050	0.8	4.50	3.70	0.980	0.979	0.992	0.997	0.792	0.970
0	0.15	0.1500	0.8	2.25	1.45	0.714	0.662	0.587	0.964	0.022	0.988

Note: A total of 1716 subjects were randomized (1:1 randomization ratio) and had a control infection rate of 15%.